RxDoctor Payments Data

Lori Williams, PA

Physician Assistant · Hays, KSNPI 1801869672

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 93.4% of the total across 458 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 60 manufacturers, the largest accounting for just 7.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $3,334 and has fallen 69.6% since, to $1,015 in 2025. Among physician assistant clinicians in KS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$8,662in general payments, 2019–2025

Across 458 payments — averaging $18.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$632
  • Bristol Myers Squibb$522
  • Seagen Inc.$435
  • E.r. Squibb & Sons, L.L.C.$414
  • Pfizer$402
  • Astellas Pharma US Inc$377
  • plus $6K from 54 others

What the payments were for

  • Food & beverage$8,09093%
  • Education$5727%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis35$632
Bristol Myers Squibb31$522
Seagen Inc.15$435
E.r. Squibb & Sons, L.L.C.29$414
Pfizer32$402
Astellas Pharma US Inc10$377
Gilead(2 entities)21$373
Johnson & Johnson17$372
Genentech USA, Inc.24$319
Merck15$300
GSK16$284
Amgen12$242
Sanofi9$226
AstraZeneca12$220
Array Biopharma Inc16$218
AbbVie11$212
Exelixis Inc.8$193
Tersera Therapeutics LLC6$190
Incyte Corporation10$180
Regeneron Healthcare Solutions, Inc.5$178
Lilly USA, LLC9$173
EMD Serono, Inc.12$137
Takeda Pharmaceuticals U.S.A., Inc.5$125
Sobi, Inc5$108
AVEO Pharmaceuticals, Inc.4$105
Pharmacyclics LLC, An Abbvie Company4$95
Jazz Pharmaceuticals Inc.4$87
Daiichi Sankyo Inc.4$84
Rigel Pharmaceuticals, Inc.4$83
Karyopharm Therapeutics Inc.4$72
Springworks Therapeutics, Inc.3$70
Genmab U.S., Inc.3$67
G1 Therapeutics, Inc.4$67
Puma Biotechnology, Inc.4$66
Ipsen Biopharmaceuticals, Inc3$64
Kyowa Kirin, Inc.4$64
Bayer3$61
Novocure Inc.3$60
Apellis Pharmaceuticals, Inc.3$58
Eisai Inc.3$57
Taiho Oncology, Inc.3$55
Stemline Therapeutics Inc.3$52
Emmaus Medical, Inc.2$50
Sumitomo Pharma America, Inc.2$46
Sun Pharmaceutical Industries Inc.2$45
Adaptive Biotechnologies Corporation2$43
Mylan Institutional Inc.2$42
Acrotech Biopharma Inc.3$40
Agios Pharmaceuticals, Inc.2$38
Beigene USA, Inc.3$37
Mirati Therapeutics, Inc.2$36
Epizyme, Inc.2$34
Pharmaessentia USA Corporation1$32
Geron Corporation1$21
Clovis Oncology, Inc.1$21
Genentech, Inc.1$18
Pharmacosmos Therapeutics Inc.1$17
CTI Biopharma Corp.1$15
Syndax Pharmaceuticals, Inc.1$15
Blueprint Medicines Corporation1$13

How this compares

$8,662 in reported general payments places this provider in the 95th percentile of 1,016 physician assistant providers in Kansas.

See all physician assistant providers in Kansas

Medicare billing

Part B allowed, 2024
$60,696
Medicare patients
288
Services billed
1,013

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban12$6,024
Exemestane13$2,800
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen25$421
Tamoxifen Citrate18$399
Hydrocortisone11$371
Anastrozole36$366
Hydroxyurea17$352
Letrozole22$336
Gabapentin43$279
Acyclovir26$247
Potassium Chloride18$221
Famotidine25$187
Oxycodone Hcl12$186
Dexamethasone12$177
Levofloxacin15$138

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$402$6,02412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,016 physician assistant providers in Kansas.

Other physician assistant in Hays

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →